---
document_datetime: 2023-09-21 22:13:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/opfolda-epar-all-authorised-presentations_en.pdf
document_name: opfolda-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7328092
conversion_datetime: 2025-12-18 10:04:15.402261
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form   | Route of administration   | Immediate Packaging   | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|-----------------------|-------------|
| EU/1/23/1737/001 | Opfolda           | 65 mg      | Capsule, hard         | Oral use                  | bottle (HDPE)         | 4 capsules  |
| EU/1/23/1737/002 | Opfolda           | 65 mg      | Capsule, hard         | Oral use                  | bottle (HDPE)         | 24 capsules |